Basiliximab Injectable Solution 20 mg/vial Suppliers & Bulk Manufacturers

Available Forms: Injectable Solution

Available Strengths: 20 mg/vial

Reference Brands: Simulect(US)

Category: Transplant

Basiliximab is a monoclonal antibody that targets the IL-2 receptor on activated T-cells, inhibiting their proliferation and immune response. It effectively reduces organ rejection in transplantation, supporting graft survival. Benefits include targeted immunosuppression, decreased rejection risk, and improved transplant outcomes, enhancing long-term graft function and patient survival.

Product Description: Basiliximab injection, marketed as Simulect, is approved in the US by the FDA and in the EU via EMA for preventing organ rejection in kidney transplantation. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews extensive clinical trial and quality data, while the EMA ensures compliance with safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports timely approval, safe use, and broad availability, helping transplant patients achieve graft survival and improve long-term outcomes worldwide.